ArticleCancer medicine2026
Prognostic Impact of PD-L1 Expression in Ovarian Cancer: Analysis of a Real-World Cohort Treated With Primary Platinum-Based Chemotherapy.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundProgrammed death-ligand 1 (PD-L1) has emerged as a potential biomarker for prognosis and treatment response in various solid tumors. However, its clinical relevance in ovarian carcinoma (OC) remains unclear, with published studies reporting inconsistent associations with platinum sensitivity and survival. These discrepancies are likely related to the biological heterogeneity of OC and methodological variability in PD-L1 evaluation. In the absence of a standardized, OC-specific assessment methodology, the Combined Positive Score (CPS) with cutoffs of ≥ 1 and ≥ 10, applied in other tumor types, represents a pragmatic approach.
methodsWe retrospectively analyzed a real-world cohort of 146 patients with ovarian carcinoma treated with primary platinum-based chemotherapy at University Hospital Brno between 2010 and 2020. PD-L1 expression was assessed using the 22C3 antibody and CPS methodology on archival, treatment-naive tumor samples obtained from primary tumors or metastatic lesions. Associations between PD-L1 status, platinum treatment-free interval (TFIp), and disease-specific survival (DSS) were evaluated, including subgroup analyses by histological subtypes.
resultsAmong the 144 evaluable cases, 65 patients (45%) demonstrated positive PD-L1 expression (CPS ≥ 1), while 35 patients (24%) exhibited strong positive expression (CPS ≥ 10). In the high-grade serous carcinoma (HGSC) subgroup, CPS ≥ 1 and CPS ≥ 10 were detected in 58/121 (48%) and 30/121 (25%) cases, respectively. PD-L1 positivity did not differ significantly between HGSC and non-HGSC subtypes or between primary and metastatic lesions. PD-L1 positivity defined as CPS ≥ 10 was significantly associated with platinum sensitivity (TFIp ≥ 6 months; p = 0.035 overall; p = 0.028 in HGSC) and longer DSS (p = 0.029). No associations were observed when PD-L1 positivity was defined using a CPS ≥ 1 cutoff.
conclusionsPD-L1 expression assessed by CPS, particularly at a cutoff of ≥ 10, may have prognostic relevance in ovarian cancer and could help identify patients more likely to benefit from platinum-based chemotherapy. Prospective validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.